In the last 10 years, several thousand patients have been treated with gene-modified adenoviral vectors in experimental studies. From a safety standpoint, low-grade febrile episodes and flu-like symptoms have been common acute treatment-related symptoms. However, long-term follow-up has not been reported. We report here more than 10 years of follow-up of 146 patients with stage IIIB or IV non-small-cell lung cancer (NSCLC) who underwent treatment through involvement in eight FDA/ IRB-approved clinical trials from 1995 to 2005 1-6 with gene-modified adenoviral-based therapeutics. All patients were managed at the Mary Crowley Medical Research Center (MCMRC).
Acute safety results of 115 out of the total 146 patients have already been published. [1] [2] [3] [4] [5] [6] Characteristics of the 146 patients include 66 females and 80 males, 14 stage IIIB patients and 132 stage IV and median age of 61 (range 19-85). Long-term follow-up of reported adverse events revealed no grade III or grade IV adverse events attributed to the investigational agent(s). Kaplan-Meier analysis of survival is shown in Figure 1 .
Mean survival was 334 days (95% CI: 269-400). Gender, age, histologic type or stage (IIIB, IV) did not significantly affect survival. The proportion of patients alive at 1 year (30%), 2 years (12%) and 5 years (6%) is consistent with historical experience. 7 Recent large randomized controlled trials involving current therapeutic choices for second line advanced NSCLC with Alimta, Docetaxel and Tarceva reveal 30, 30 and 28% 1-year survival, respectively. [7] [8] [9] Historical survival of placebotreated patients at 1 year was 18%. 8 Several limitations exist when comparing historical data to prospective trial results in an uncontrolled analysis. We conclude, however, given the lack of any significant long-term reported adverse events and comparable survival to similar historical patients, that there are no obvious concerns towards the long-term effect of therapy involving adenoviral vectors in NSCLC patients. In conclusion, with respect to safety, these results support continued development of adenoviral-based therapy as a primary oncolytic and as a gene delivery vehicle. www.nature.com/cgt
